BV Study

计划入组 39 人

CAP 098 (BV Study)

计划入组 150 人 · 首次发布于 2026 年 7 月 6 日

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

计划入组 81 人 · 首次发布于 2019 年 4 月 29 日

BV-200 series

BV-5200

BV-4231

Acerta Pharma BV

Netherlands

ViiV Healthcare BV

Netherlands

Celgene Europe BV

Netherlands

ProteoNic's 2G UNic Technology Licensed by Ginkgo Bioworks for $22.2M BARDA-Funded Anti-Filovirus Antibody Manufacturing Project

ProteoNic Launches 2G UNic Transposon Platform for Enhanced Biologics Production

Citryll Secures €85 Million in Series B Funding to Advance NET-Targeting Antibody CIT-013